SOPHIA ANTIPOLIS CEDEX, FRANCE -- (Marketwired) -- 04/26/13 -- Nicox S.A. (NYSE Euronext
Paris: COX) today announced that the Company's Board
of Directors has nominated Vicente Anido, Jr., PhD., to be elected to the
Dr. Anido is a highly respected and experienced leader in the
sector. He most recently served as President and Chief Executive Officer of
Pharmaceuticals prior to its acquisition by Bausch + Lomb. The election of
Anido to Nicox's Board will be voted on at the Company's 2013 Ordinary
Shareholder Meeting, which will be convened for June 6, 2013.
"The Board is pleased to propose Vince Anido as a Board member of Nicox.
has a wealth of experience in the management of pharmaceutical companies,
particularly in the ophthalmic area. We believe he would be a significant
addition to the existing strength and combined experience of the Nicox
we work towards building an international ophthalmology business," said
Garufi, Chief Executive Officer of Nicox.
About Vicente Anido, Jr.
From 2001 to 2012, Dr. Anido was President, Chief Executive Officer and a
Director of ISTA Pharmaceuticals, a US-based ophthalmic pharmaceutical
Prior to this, he was general partner of Windamere Venture Partners, served
President and CEO of CombiChem, Inc., a biotechnology company, and was
of the Americas Region of Allergan, a specialty pharmaceutical company
on ophthalmology, dermatology and neuromuscular indications.
Dr. Anido currently serves on the Board of Directors of QLT Inc. and
Inc., two NASDAQ-listed pharmaceutical companies, and was recently named
Chairman of the Board of Directors of Aerie Pharmaceuticals, a US private
Dr. Anido received a B.S. in Pharmacy, an M.S. in Pharmacy Administration
West Virginia University and a Ph.D. in Pharmacy Administration from the
University of Missouri.
Information on the 2013 Ordinary Shareholder Meeting is available on the
Nicox internet website: http://www.nicox.com/index.php/en/investor-
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new mid-
international player in the ophthalmic market by building a
portfolio of innovative therapies and diagnostic tools. With a
scientific, business development and commercial expertise, the Nicox
focused on developing and marketing novel pharmaceuticals and diagnostic
that can help people to enhance their sight. In the United States, Nicox
AdenoPlus, a test for the differential diagnosis of acute
licensed from RPS®.
The Company's pipeline includes latanoprostene bunod, a novel drug-
based on Nicox's proprietary nitric oxide (NO)-donating R&D platform,
in collaboration with Bausch + Lomb for the potential treatment of
ocular hypertension. Further NO-donating compounds are under development in
ophthalmic indications, notably through partners, including Merck (known
outside the United States and Canada) and Ferrer.
Nicox S.A. is headquartered in France and is listed on Euronext
(Compartment B: Small Caps). For more information please visit
This press release contains certain forward-looking statements. Although
Company believes its expectations are based on reasonable assumptions,
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's
presented in the 4th chapter of the « Document de référence,
annuel et rapport de gestion 2012 » filed with the French
Autorité des Marchés
Financiers (AMF) on March 22, 2013 and available on Nicox's website
(www.nicox.com) and on the AMF's website (www.amf-france.org).
Vicente Anido, Jr. nominated for election to Nicox's Board of Director:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE
Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00
D +44 (0)20 7269 7205
M +44 (0) 7515 597 858
D +44 (0)20 3077 0458
M +44 (0) 7843 080947
2405 route des Dolines
06560 Valbonne, France
T: +33 (0)4 97 24 53 00
F: +33 (0)4 97 24 53 99